|  | Week 0 | Week 2 | Week 6 | Week 12 | Week 24 | Year 1 | Year 2 | Year 3 |
---|---|---|---|---|---|---|---|---|---|
Disease measure | Drug | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
BASDAI 50 | 0 | 41 | ~58 | 53 | Â | 47 | 41 | 47 | |
 | Etanercept [25] | 0 |  | 57 | 71 |  |  |  |  |
 | Adalimumab [13] | 0 |  |  | 43 | 51 | 56 | 59 |  |
ASAS 20 | 0 | ~50 | ~61 | ~62 | ~61 | Â | 74 | Â | |
 | 0 | 53 |  | 60 | ~76 |  | 83 |  | |
 | 0 | ~42 | ~56 | 58 | 65 |  | 65 |  | |
ASAS 40 | 0 | Â | ~32 | 50 | 47 | ~54 | 52 | 50 | |
 | Etanercept [97] | 0 |  |  | 49 | ~64 | ~62 |  | ~66 |
 | Adalimumab [13] | 0 |  | ~35 |  | 46 |  | 51 |  |
ASAS 5/6 | Infliximab [93] | 0 | Â | ~34 | ~63 | ~52 | 53 | ~48 | 46 |
 | Etanercepta [98] | 0 |  | ~50 | ~69 | ~60 | 65 |  |  |
 | Adalimumab [13] | 0 |  | ~37 | 48 | 59 | ~55 | 59 |  |
ASAS Partial Remission | Infliximab [71] | 0 | ~10 | ~17 | ~21 | 22 | ~23 | ~29 | Â |
 | Etanercepta [98] | 0 |  | 31 | 31 | ~27 | 31 |  |  |
 | Adalimumab [13] | 0 |  | ~20 | 21 | 24 |  | 34 |  |